Skip to content

Augmented Care at Worksite for Diabetes Prevention

Impact of Augmented Care at the Worksite for Diabetes Prevention

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03382873
Enrollment
208
Registered
2017-12-26
Start date
2018-02-08
Completion date
2022-04-15
Last updated
2024-04-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PreDiabetes

Keywords

Hyperglycemia, Obese, Overweight

Brief summary

The purpose of the study was to evaluate the impact of augmented care at the worksite through a lifestyle intervention for diabetes prevention among employees with prediabetes who were slower to respond to a standard diabetes prevention intervention.

Detailed description

Employees at the Ohio State University (OSU) with prediabetes participated in a standard lifestyle intervention (Group Lifestyle Balance) for diabetes prevention. Participants who did not achieve \>2.5% weight loss at week 5 of the intervention were stratified to the augmented intervention (Group Lifestyle Balance Plus) at week 5. The impact of the augmented intervention compared to the standard intervention was determined at 4, 12 and 18 months from baseline to determine if implementing early enhanced training helped participants achieve and maintain weight loss similar to those who received the standard intervention.

Interventions

BEHAVIORALGroup Lifestyle Balance (GLB)

The intervention included the following key features: group-based sessions led by a lifestyle coach; a structured, state-of-the-art, 16-session core-curriculum that emphasized behavioral self-management strategies for weight loss and physical activity; 8-months of extended care with bimonthly or monthly sessions; self-monitoring of diet and physical activity.

BEHAVIORALGroup Lifestyle Balance Plus (GLB+)

The GLB+ intervention arm included participants who did not achieve the targeted percent weight loss by week 5 and incorporated enhanced training in values clarification, mindful decision making, planning, and problem solving. GLB+ included the same number of group-based sessions as GLB.

Sponsors

Ohio State University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Intervention model description

The proposed translational study applied an innovative experimental approach, an adaptive design, to optimize treatment for weight loss and weight loss maintenance in individuals with prediabetes. All participants initiated a standard lifestyle intervention to promote weight loss. Those who did not achieve \>2.5% weight loss during the first month of the intervention were stratified to augmented care to enhance weight loss during the intensive intervention phase. Following the intensive phase, participants were randomly assigned to either the standard intervention or the enhanced intervention for the maintenance study phase. By randomly assigning participants to either the standard maintenance phase of the intervention or the innovative maintenance phase of the intervention following the initial core phase, the impact of extended training in self-regulation for weight loss maintenance was evaluated.

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Benefits-eligible Ohio State University (OSU) employee 2. Intend to be employed by OSU through the length of the follow-up phase 3. Body mass index: \>24 kg/m\^2 non-Asians; \>22 kg/m\^2 Asians 4. Fasting blood glucose of 100-125 mg/dL or an A1c of 5.7-6.4% 5. Blood glucose of 110-199 (if non-fasting in previous 2 hours)

Exclusion criteria

1. Blood glucose level of ≥ 200 mg/dL 2. Conditions that would limit adoption of light/moderate physical activity (i.e., cardiac event, severe chronic obstructive pulmonary disease, advanced arthritis, poorly controlled hypertension) 3. Chronic use of medications that affect blood glucose levels (i.e., corticosteroids) 4. Concurrent participation in a structured weight loss program or counseling for bariatric surgery 5. Pregnant or breastfeeding 6. Score of ≥ 10 on the Patient Health Questionnaire-8 indicating moderate to severe depressive symptoms 7. Score of ≥ 27 on the Binge Eating Scale indicating the potential for binge eating 8. Unwilling to accept randomization 9. Planning to move from the area or changing employment.

Design outcomes

Primary

MeasureTime frameDescription
Percent Weight Changebaseline and 4-monthsChange in weight as measured in light clothing and shoes removed

Secondary

MeasureTime frameDescription
Fasting Glucosebaseline and 4-monthsFasting glucose from a fingerstick sample

Countries

United States

Participant flow

Recruitment details

Employees from a Midwestern university with overweight or obesity and prediabetes were recruited from 2018-2021.

Pre-assignment details

Participants completed 4 weeks of the standard Group Lifestyle Balance (GLB) intervention. Those who achieved \>2.5% weight loss at week 5 remained in GLB at week 5. Those who achieved \<2.5% weight loss at week 5 were stratified to the GLB Plus (GLB+) intervention at week 5. Participants were paired based on percent weight change at month 5. Each member in the pair was randomized to group at month 5 for the study duration. Thus, group sample sizes are different at month 5 compared to month 4.

Participants by arm

ArmCount
Group Lifestyle Balance (GLB)
Standard lifestyle intervention
80
Group Lifestyle Balance Plus (GLB+)
Augmented lifestyle intervention for slow responders
111
Total191

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyLost to Follow-up910
Overall StudyVisit not completed due to pandemic1641
Overall StudyWithdrawal by Subject611

Baseline characteristics

CharacteristicTotalGroup Lifestyle Balance Plus (GLB+)Group Lifestyle Balance (GLB)
Age, Continuous52.1 years
STANDARD_DEVIATION 10.1
51.5 years
STANDARD_DEVIATION 10.2
52.7 years
STANDARD_DEVIATION 10
Body weight102.5 kg
STANDARD_DEVIATION 1.8
102.5 kg
STANDARD_DEVIATION 2.3
102.6 kg
STANDARD_DEVIATION 2.7
Ethnicity (NIH/OMB)
Hispanic or Latino
5 Participants4 Participants1 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
184 Participants105 Participants79 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
2 Participants2 Participants0 Participants
Fasting glucose108.1 mg/dL
STANDARD_DEVIATION 0.71
107.58 mg/dL
STANDARD_DEVIATION 0.99
109.24 mg/dL
STANDARD_DEVIATION 1.14
Race (NIH/OMB)
American Indian or Alaska Native
1 Participants1 Participants0 Participants
Race (NIH/OMB)
Asian
13 Participants8 Participants5 Participants
Race (NIH/OMB)
Black or African American
23 Participants18 Participants5 Participants
Race (NIH/OMB)
More than one race
1 Participants1 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
2 Participants2 Participants0 Participants
Race (NIH/OMB)
White
151 Participants81 Participants70 Participants
Sex: Female, Male
Female
140 Participants90 Participants50 Participants
Sex: Female, Male
Male
51 Participants21 Participants30 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 861 / 122
other
Total, other adverse events
4 / 8613 / 122
serious
Total, serious adverse events
2 / 863 / 122

Outcome results

Primary

Percent Weight Change

Change in weight as measured in light clothing and shoes removed

Time frame: baseline and 4-months

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
Group Lifestyle Balance (GLB)Percent Weight Change-8.13 percent changeStandard Error 0.48
Group Lifestyle Balance Plus (GLB+)Percent Weight Change-3.46 percent changeStandard Error 0.31
p-value: <0.0001ANOVA
Primary

Percent Weight Change

Change in weight as measured in light clothing and shoes removed

Time frame: baseline and 12-months

Population: Compares the change for the GLB/GLB intervention sequence to the GLB+/GLB+ intervention sequence (the primary comparison of interest at 12-months)

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
Group Lifestyle Balance (GLB)Percent Weight Change-9.55 percent changeStandard Error 0.96
Group Lifestyle Balance Plus (GLB+)Percent Weight Change-4.00 percent changeStandard Error 1.05
Comparison: Compares the change for the GLB/GLB intervention sequence to the GLB+/GLB+ intervention sequence (the primary comparison of interest)p-value: 0.0001ANOVA
Primary

Percent Weight Change

Change in weight as measured in light clothing and shoes removed

Time frame: 12-months and 18-months

Population: Compares the GLB/GLB intervention sequence to the GLB+/GLB+ intervention sequence (the primary comparison of interest at 18-months for weight loss maintenance)

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
Group Lifestyle Balance (GLB)Percent Weight Change2.22 percent changeStandard Error 0.59
Group Lifestyle Balance Plus (GLB+)Percent Weight Change2.28 percent changeStandard Error 0.56
Comparison: Comparison of the GLB/GLB intervention sequence to the GLB+/GLB+ intervention sequence (the primary comparison of interest).p-value: 0.9476ANOVA
Secondary

Fasting Glucose

Fasting glucose from a fingerstick sample

Time frame: baseline and 4-months

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
Group Lifestyle Balance (GLB)Fasting Glucose-7.01 mg/dLStandard Error 1.13
Group Lifestyle Balance Plus (GLB+)Fasting Glucose-3.18 mg/dLStandard Error 0.98
p-value: 0.0112ANOVA
Secondary

Fasting Glucose

Fasting glucose from a fingerstick sample

Time frame: baseline and 12-months

Population: Compares the GLB/GLB intervention sequence to GLB+/GLB+ intervention sequence (the primary comparison of interest at 12-months)

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
Group Lifestyle Balance (GLB)Fasting Glucose-4.30 mg/dLStandard Error 1.57
Group Lifestyle Balance Plus (GLB+)Fasting Glucose-4.04 mg/dLStandard Error 1.7
Comparison: Comparison of GLB/GLB intervention sequence to GLB+/GLB+ intervention sequence (the primary comparison of interest).p-value: 0.9085ANOVA
Secondary

Fasting Glucose

Fasting glucose from a fingerstick sample

Time frame: 12-months and 18-months

Population: Compares the GLB/GLB intervention sequence to the GLB+/GLB+ intervention sequence (the primary comparison of interest at 18-months)

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
Group Lifestyle Balance (GLB)Fasting Glucose-1.21 mg/dLStandard Error 2.28
Group Lifestyle Balance Plus (GLB+)Fasting Glucose2.71 mg/dLStandard Error 2.08
Comparison: Comparison between the GLB/GLB intervention sequence and the GLB+/GLB+ intervention sequence (the primary comparison of interest)p-value: 0.2063ANOVA

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026